CD8A and neoplasm: This was recently shown to be due to losartan enhancing CD8+ T-cell infiltration and decreasing Tregs in the TME and reducing immunosuppressive FoxP3+ cancer cells, thus enhancing anti-tumor immunity and tumor cell killing (214).